Expora Therapeutics

Expora Therapeutics is a biotechnology company specializing in the design and manufacturing of bacterial extracellular vesicles (BEVs). Spun out of the University of Maryland, the company has developed a patent-pending platform, the Expora Platform, which overcomes traditional manufacturing barriers to enable the scalable, consistent, and cost-effective production of BEVs. By utilizing these nano-sized particles produced by probiotic bacteria, Expora provides a non-living, cell-free alternative to traditional probiotics, allowing for precise, predictable, and potent delivery of bioactive payloads. The company's technology includes advanced engineering capabilities to modify BEV payloads, such as small molecules, proteins, peptides, or RNA, for targeted therapeutic applications.

Expora operates as a contract development and manufacturing organization (CDMO) and maintains its own therapeutic research and development programs. Its technology addresses critical challenges in human health, particularly in areas like gastrointestinal disease, by offering a drug delivery vehicle that avoids the viability issues associated with live bacteria. By providing a scalable, industrial-grade GMP process for BEVs, Expora serves pharmaceutical and consumer health partners looking to advance novel exosome-based therapies. The company is based in Frederick, Maryland, and is focused on building out its manufacturing and quality systems to scale its platform for diverse therapeutic and consumer applications.